Overall, our results show altered BM proliferation profiles in MDS, which significantly differ in early/low-risk vs. advanced/high-risk subtypes of the disease: increased proliferation of myeloid CD34+ precursors, maturing neutrophils and NRBC in early phases of the disease, and progressively decreased PI in advanced MDS and AML. This evidence concerns the gene CD34 and acute myeloid leukemia.